Literature DB >> 10551583

Effects of dobutamine on hemodynamics and left ventricular performance after cardiopulmonary bypass in cardiac surgical patients.

J L Romson1, J M Leung, W H Bellows, M Bronstein, F Keith, W Moores, K Flachsbart, R Richter, D Pastor, D M Fisher.   

Abstract

BACKGROUND: Dobutamine is commonly used to improve ventricular performance after cardiopulmonary bypass. The authors determined the effect of dobutamine on hemodynamics and left ventricular performance immediately after cardiopulmonary bypass in patients undergoing coronary artery bypass graft surgery.
METHODS: One hundred patients received sequential 3-min infusions of dobutamine at 0-40 microg x kg(-1) x min(-1) immediately after cardiopulmonary bypass. Ten additional patients who received no dobutamine served as controls. Hemodynamics and left ventricular performance (fractional area change by transesophageal echocardiography, stroke volume index, and thermodilution cardiac index) were measured. Mixed-effects modeling accounted for repeated-measures data and interindividual differences and allowed for potential effects of covariates.
RESULTS: Heart rate increased in a dose-dependent manner. The slope of HR versus dobutamine dose was steeper in individuals in whom peak dobutamine dose was not reached compared with that in the remaining individuals; slope decreased 2.71 +/- 0.68% per year of age. Dobutamine affected blood pressure minimally, but slightly decreased pulmonary capillary wedge pressure and central venous pressure. Systemic vascular resistance initially increased with dobutamine 10 microg x kg(-1) x min(-1) and remained constant with larger doses. Dobutamine produced a dose-dependent increase in left ventricular performance, primarily by increasing heart rate, because stroke volume index decreased with dobutamine dose.
CONCLUSION: Our results suggest that the response to graded dobutamine infusion in the post-cardiopulmonary bypass period differs from that previously reported. After cardiopulmonary bypass, the dominant mechanism by which dobutamine improves left ventricular performance is by increasing heart rate. Dobutamine affects blood pressure minimally.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10551583     DOI: 10.1097/00000542-199911000-00024

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  8 in total

1.  Use of ivabradine in catecholamine-induced tachycardia after high-risk cardiac surgery.

Authors:  Domenico Vitale; Vincenzo De Santis; Fabio Guarracino; Andrea Fontana; Fabio Pellegrini; Luigi Tritapepe
Journal:  Clin Res Cardiol       Date:  2010-09-07       Impact factor: 5.460

2.  The diagnostic value of Doppler echocardiographic indexes of diastolic filling for detecting demand ischemia in anesthetized patients.

Authors:  M D Seeberger; M Filipovic; R Rohlfs; O Dergeloo; W Studer; D Atar; P Buser; K Skarvan
Journal:  Int J Card Imaging       Date:  2000-12

3.  Pharmacokinetic-pharmacodynamic relationship of dobutamine and heart rate, stroke volume and cardiac output in healthy volunteers.

Authors:  Jouni Ahonen; Kari Aranko; Aija Iivanainen; Eeva-Liisa Maunuksela; Markku Paloheimo; Klaus T Olkkola
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

Review 4.  Bench-to-bedside review: Inotropic drug therapy after adult cardiac surgery -- a systematic literature review.

Authors:  Michael Gillies; Rinaldo Bellomo; Laurie Doolan; Brian Buxton
Journal:  Crit Care       Date:  2004-12-16       Impact factor: 9.097

5.  Intravenous ivabradine versus placebo in patients with low cardiac output syndrome treated by dobutamine after elective coronary artery bypass surgery: a phase 2 exploratory randomized controlled trial.

Authors:  Lee S Nguyen; Pierre Squara; Julien Amour; Daniel Carbognani; Kamel Bouabdallah; Stéphane Thierry; Caroline Apert-Verneuil; Aurélie Moyne; Bernard Cholley
Journal:  Crit Care       Date:  2018-08-17       Impact factor: 9.097

Review 6.  Shock - Classification and Pathophysiological Principles of Therapeutics.

Authors:  Olga N Kislitsina; Jonathan D Rich; Jane E Wilcox; Duc T Pham; Andrei Churyla; Esther B Vorovich; Kambiz Ghafourian; Clyde W Yancy
Journal:  Curr Cardiol Rev       Date:  2019

Review 7.  Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper.

Authors:  Bernard Cholley; Bruno Levy; Jean-Luc Fellahi; Dan Longrois; Julien Amour; Alexandre Ouattara; Alexandre Mebazaa
Journal:  Crit Care       Date:  2019-11-29       Impact factor: 9.097

8.  Effect of Levosimendan Compared to Conventional Inotropic Agents on Hemodynamics and Outcome in Patient with Poor LV Function Undergoing Cardiac Surgery.

Authors:  Mahmoud Khaled; Ahmad Naem Almogy; Mohammed Shehata; Fahim Ragab; Khaled Zeineldin
Journal:  Open Access Maced J Med Sci       Date:  2019-08-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.